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Thirty-six urological patients (21 male, IS female) aged 21 to 83 years with compli-
cated and/or hospital-acquired urinary tract infections due to sensitive bacteria
were treated with ceftazidime intravenously with a daily dose of 2 g bd over 5 to 17
days. Twenty-seven patients were followed for 1 to 4 weeks after therapy. Cure was
observed in 41 %, reinfection in 33% and relapse in 26% of the patients. Eradication
of the original pathogen occurred in 74%. Five patients showed minor side effects:
diarrhoea (2), nausea (1), rash (1), headache (1). No signs of renal, hepatic or
haematological toxicity were observed.
A pharmacolcinetic study was performed in 13 elderly patients aged 63 to 83 years
on day 1 of treatment and in 6 volunteers aged 24 to 32 years following administration
of 2 g of ceftazidime as short intravenous infusion. The mean serum half life in 12
patients 2-9 h significantly higher than in volunteers (1-75 h). Serum concentrations in
patients on day 7 of treatment, however, showed no accumulation when treated with
a dosage of 2 g bd.
Introduction
Ceftazidime is currently used in the treatment of complicated urinary tract infections
because of its broad-spectrum antibacterial activity especially against Gram-negative
bacteria including Pseudomonas spp. (Harper, 1981). Its pharmacokinetic properties
include a terminal serum half life of approximately 1-8 h, renal excretion by glomerular
nitration with an 88% urinary recovery in 24 h and a low protein binding of about 10%.
No metabolites are found in serum or urine (Harding et al., 1981). In the present study
the therapeutic efficacy with complicated and/or hospital-acquired urinary tract infections
in urological patients and the pharmacokinetic parameters in elderly patients as
compared to young volunteers were evaluated.
Materials and methods
A total of 36 urological patients (21 male, 15 female) aged 21 to 83 years (median 77
years) with complicated and/or hospital acquired urinary tract infections (defined as
colony counts ^ 10*/ml) were treated with ceftazidime 2 g bd by short intravenous
infusion over 5 to 17 days (median 8). Three of these patients (2 male, 1 female) had
moderate renal insufficiency (serum creatinine 1 1 to 2-4 mg/dl). In one male patient aged
77 years the therapy was discontinued after 2 days because of nausea. Thirteen of the
21 male patients had an indwelling catheter. In 9 patients a catheter was used transiently
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(2 to 12 days, median 4). Only in 3 patients could the catheter not be removed before
or during therapy.
Midstream or catheter urine in males and catheter urine in females, was collected
before, during, 1 to 6 days and again 1 to 4 weeks after the end of therapy. Counting
and identification of isolates was performed by standard methods and the API-20B
system. Agar susceptibility of bacteria was determined by an agar-diffusion method
according to ICS recommendations with Mueller-Hinton agar (Merck) and 10 fig discs
(diameter 6 mm) of ceftazidime. Organisms with a zone diameter of 17 mm and more
were classified as sensitive, corresponding to an MIC of < 16 mg/1 (Grimm, 1981).
The therapeutic results were determined according to the bacteriological findings, since
most of the patients had no clinical symptoms. Only six patients had febrile episodes
prior to therapy. Cure was diagnosed if patients showed sterile urine or bacteruria with
colony counts of less than lOVml during therapy and during follow up period. Since
some patients could not be followed longer than 1 to 6 days after treatment, these patients
-were classified as provisional cures, if the above mentioned urine criteria were met during
this time. These patients were not included, however, in the final assessment. Patients
with colony counts of greater than 10*/ml were classified as reinfection (new species) or
as relapse (same species). These criteria were divided into 'early' and 'late', when the
diagnosis was confirmed during the early (1 to 6 days) or late (1 to 4 weeks) follow-up
period. In order to monitor tolerance of the antibiotic before, during and after treatment,
the patients' clinical course was monitored and the following tests were carried out:
haemoglobin, haematocrit, differential blood count, platelet count, blood-urea nitrogen,
serum creatinine, GOT, GPT, gamma GT and alkaline phosphatase. Urinalysis included
quantitation of leucocytes and erythrocytes, albumin and glucose.
A pharmacokinetic study was performed following administration of 2 g of ceftazidime
as a bolus intravenous injection in 13 (11 male, 2 female) of these 36 patients aged 63
to 83 years (median 77) with a body weight of 55 to 96 kg (median 71), a height of 152
to 178 cm (median 166) and a serum creatinine of 0-7 to 1-5 mg/dl (median 11) and in
6 younger volunteers (3 male, 3 female) aged 24 to 32 years (median 26) with a body
weight of 54 to 81 kg (median 63), a height of 153 to 184 cm (median 169) and a serum
creatinine of 0-4 to 0-9 mg/dl. Venous blood samples were drawn from the contralateral
arm before, and 6, 15, and 30 min, and 1, 2, 3, 4, 6, 10 h and, in volunteers, 12 h after
start of administration. In addition, serum concentrations were measured on day 7 of
treatment before, and 1, 2 and 4 h after administration of 2 g ceftazidime intravenously.
Urine was collected up to 12 h.
Serum and urine were kept frozen at — 20°C until analysis by HPLC method modified
according to Ayrton (1981). The pharmacokinetic parameters were calculated by Glaxo
Research, Greenford, using an open two-compartment model. Statistical analysis was
performed using mean ( ± S . D . ) values and the /-test, in which P < 005 was taken as
statistically significant.
Results
Therapeutic study
Thirty-five patients (20 male, 15 female) treated for 5 days or longer could be evaluated
up to 1 to 6 days and 27 patients (16 male, 8 female) up to 1 to 4 weeks after the end
of treatment. The bacterial species isolated before therapy are listed in Table I. All strains
showed inhibition diameters of 1 -7 mm or more and were therefore classified as sensitive.
In all patients with febrile episodes the fever disappeared within 2 days. During therapy
only one patient infected originally by Pseudomonas fluorescens later had urine inf~~ rom
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Table L Bacterial isolates before treatment with ceftazidime
Bacterial species
Monoinfections:
E.coli
Pr. mirabilis
Pr. vulgaris
Pr. inconslans
Ps. aeruginosa
Ps. fluorescent
Klebsiella sp.
Ent. sakazaku
Ser. marcescens
Citro. freundii
Staph. aureus
Mixed infections:
E. coli+
Pr. mirabilis
No. of patients
Male
8
2
1
1
3
1
1
1
1
—
1
—
20
Table II. Bacterial isolates during and after treatment
Male
Bacterial species Relapse/reinfection
Monoinfections:
E. coli
Pr. mirabilis
Ps. aeruginosa
K. pneumoniae
Str. faecalis
Staph. aureus
Mixed infection:
Staph. aureus +
Str. faecalis
No. of patients
3
— —
1 —
— 1
— 5
1 —
— 1
5 7
Female
8
2
—
—
1
—
1
—
—
1
—
2
15
of therapy with ceftazidime
Female
Relapse/reinfection
1 1
1 1 •
— —
— —
— —
— —
— —
2 2
with Streptococcus faecalis and Candida albicans. One to 6 days after therapy 2 further
male patients had early reinfections with colony counts of 10</ml {Klebsiella pneumoniae,
Str. faecalis). Of the 32 patients with colony counts of less than \0*/ml 1 to 6 days after
treatment only 21 could be followed up to 1 to 4 weeks after treatment. Eight patients
(4 male, 4 female) had no infection during this time, six (4 male, 2 female) showed
reinfection (late) and 7 (5 male, 2 female) relapsed (late). The bacteria found during
therapy and the follow-up period are listed in Table II. Serotyping of E. coli was not
performed.
The local and systemic tolerance of ceftazidime were good as judged by clinical and
laboratory tests are concerned. In one patient the treatment had to be discontinued after
2 days because of nausea. Five additional patients showed clinical side effects: nausea
(1), headache (1), diarrhoea (2), rash (1) on day 4 of treatment. There were no signs of
haematological, hepatic or renal toxicity.
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Figure 1. Mean (±s.D.) serum concentrations (mg/1) of ceftazidime in younger volunteers (n = 6) aged 24
to 32 years and elderly patients (n = 13) aged 63 to 83 years following intravenous administration of 2 g.
Table HI. Mean (±S.D.) renal excretion (% of given dose) of ceftazidime in young volunteers
(« = 6) and elderly patients (n = 13) up to 12 h following intravenous injection of 2 g of
ceftazidime
% renal excretion during urine collection time (h)
0-2 2-4 4-8 8-12
Volunteers
Patients
59-9 ±4-9
27-7 ±6-4
751 ±3-5
43-4±100
83-9±7-9
57-3±18-3
86-3 ±8-4
69 4±11 6
Table IV. Mean (±s.D.) phannacokinetic parameters for ceftazidime following administration of
2 g iv in young volunteers (n = 6) and elderly patients (n = 12) on day 1 of treatment (2 g bd)
Parameter Volunteers Patients
Serum half life (h)
Serum clearance (ml/min)
Volume of distribution
(% of body weight)
l-75±014
123±11
18-9±l-5
2-9±0-5
79±17
19-4±30
Pharmacokinetic study
Figure 1 shows the mean serum concentrations (±S.D.) of the group of patients and
volunteers following intravenous injection of 2 g of ceftazidime. The mean serum
concentrations in patients (volunteers) were found to be highest at 6 min with 173 mg/1
(210 mg/1) and fell to 76 mg/1 (70 mg/1) at 1 h, to 35 mg/1 (16 mg/1) at 4h, and to
6-7 mg/1 (1-8 mg/1), at 10 h. Twelve hours after administration the mean serum concen-
tration in volunteers was 10 mg/1. The mean urinary excretions up to 12 h were in
patients 69% and in volunteers 86% of the given dose (Table III). The mean serum
concentrations in patients on day 1 and day 7 of treatment showed no accumulation
during 1 week with this dose regimen. The pharmacokinetic parameters, serum half life,
serum clearance and volume of distribution, showed a significant increase of the half life
from 1-75 in volunteers to 2-9 in patients with corresponding lowering of the clearance.
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The volume of distribution was not significantly different and corresponded to the
amount of extracellular fluid (Table IV). Between day 1 and day 7 of treatment there
was no significant difference in the phannacokinetic parameters calculated in the
patients.
Discussion
It is often difficult to cure complicated urinary tract infections. In this study the first
therapeutic aim, to control exacerbation and to prevent symptomatic infection, was
achieved in all cases. The second aim, to cure complicated urinary tract infections and
eradicate bacteriuria, was achieved in only 11 (40%) of 27 patients followed up for 1
to 4 weeks. In these 27 patients there was a high percentage of reinfection (33%) and
relapse (26%). Nevertheless the eradication of the original pathogen was possible in 74%
of these patients. These results are in agreement with the result achieved with other
broad-spectrum cephalosporins (Naber & Bauernfeind, (1982).
In elderly patients impairment of renal function must be considered even with' normal'
serum creatinine levels (Siersbeck-Nielsen et al., 1971). This results in prolongation of
serum half-lives of antibiotics excreted chiefly by the kidneys, such as cefuroxime,
cefotaxime, and cefmenoxime, (Naber, 1979; Naber & Adam, 1980; Naber et al., 1982).
Although the mean serum half-life in elderly patients was twice as long as in young
volunteers, no accumulation was observed during treatment over 7 days at a dosage of
2gbd.
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